| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.27 M USD | -18.32 M USD | -7.29 M USD | -11.22 M USD | -725618 USD | -218713 USD | — |
| Depreciation & Amortization | 27058 USD | 27923 USD | 25049 USD | 25048 USD | 16782 USD | — | — |
| Stock-Based Compensation | 595368 USD | 168850 USD | 155721 USD | 301116 USD | 470878 USD | — | — |
| Capital Expenditures | — | 19171 USD | — | — | 131963 USD | — | — |
| Cash Flow from Investing | — | -19171 USD | — | — | 25.74 M USD | -74.04 M USD | — |
| Cash Flow from Financing | 12.47 M USD | 12.85 M USD | 14.03 M USD | 15.20 M USD | -24.95 M USD | 74.27 M USD | — |
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | 35.50 M USD | — | — |
| Free Cash Flow | — | -18.34 M USD | — | — | -857581 USD | — | — |
Revelation Biosciences Inc. is a biotechnology company focused on developing diagnostic and therapeutic products to address respiratory and infectious diseases. Their primary function is to innovate in the field of healthcare with novel solutions that can detect and combat prevalent health threats. Notably, Revelation Biosciences is involved in creating point-of-care diagnostic tests that aim to quickly and efficiently identify infections, enabling timely and informed medical decisions. The company also pursues therapeutic development to improve treatment outcomes for patients suffering from respiratory ailments. Within the financial market, Revelation Biosciences contributes to the healthcare and biotech sectors, representing the intersection of technology and medicine to address critical health challenges. With a commitment to research and development, Revelation Biosciences is a key player in improving diagnostic and therapeutic approaches, thus enhancing healthcare delivery and patient care globally.